Implantable Cardioverter-Defibrillator Lead Performance

Abstract

HomeCirculationVol. 117, No. 21Implantable Cardioverter-Defibrillator Lead Performance Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBImplantable Cardioverter-Defibrillator Lead Performance William H. Maisel, MD, MPH and Daniel B. Kramer, MD William H. MaiselWilliam H. Maisel From the Medical Device Safety Institute, Department of Medicine, Beth Israel Deaconess Medical Center (W.H.M.), and Department of Medicine, Massachusetts General Hospital (D.B.K.), Boston, Mass. Search for more papers by this author and Daniel B. KramerDaniel B. Kramer From the Medical Device Safety Institute, Department of Medicine, Beth Israel Deaconess Medical Center (W.H.M.), and Department of Medicine, Massachusetts General Hospital (D.B.K.), Boston, Mass. Search for more papers by this author Originally published27 May 2008https://doi.org/10.1161/CIRCULATIONAHA.108.776807Circulation. 2008;117:2721–2723Implantable cardioverter-defibrillators (ICDs) have revolutionized the treatment of patients at risk for sudden cardiac death. In the nearly 3 decades since the first human ICD implant,1 millions of devices have been implanted worldwide and innumerable lives have been saved. Successful resuscitation of a potentially lethal ventricular arrhythmia by an ICD system depends on successful arrhythmia detection and timely delivery of therapy. Both the ICD generator and the ICD lead are critical components of this system. The lead, in particular, is literally a lifeline whose purpose is to convey critical information about the heart’s rhythm to the ICD generator and, in turn, to deliver life-sustaining therapy when needed. Failure of an ICD lead may result in significant clinical events, including failure to pace, failure to defibrillate, inappropriate shocks, and even death.Article p 2727ICD leads, like many medical technologies, have undergone a remarkable transformation. Epicardial leads, which necessitated a thoracotomy for lead placement, have given way to transvenous leads, which are easier to implant, less costly, and associated with decreased morbidity and mortality.2 Important advances in transvenous lead technology, such as the development of steroid elution, smaller diameter leads, novel insulations, and multipolar leads, have translated into meaningful clinical benefits for patients. Although modern ICD leads consist primarily of electrodes, conductors, insulation, and a fixation mechanism to attach the lead to the myocardium, lead design and performance vary from model to model. Indeed, monitoring of performance is critical not only to identify products with increased failure rates but also to provide physicians and patients with realistic expectations of device performance.In the current issue of Circulation, Eckstein et al add to our understanding of ICD lead performance.3 The investigators conducted a retrospective analysis of 1317 consecutive patients who received ICD systems (including 38 different ICD lead models) at 3 centers in Germany between 1993 and 2004. Follow-up after implantation included noninvasive routine lead evaluation every 3 to 6 months. Lead failure was defined as a lead-related problem requiring surgical revision performed at the discretion of the treating physician. Abnormalities were classified as either structural (insulation defects or lead fracture) or functional (far-field sensing; T-wave or physiological oversensing, noise from contact with another lead, unstable impedance measurements, R-wave reduction, or loss of capture).During a median follow-up of 6.4 years, 38 ICD leads required surgical revision, resulting in a reported cumulative ICD lead survival rate of 97.5% at 5 years. Compared with previous reports on ICD lead performance, this failure rate is low. This low rate could be due to underdetection of lead failures, a high clinical threshold for replacing a failed lead, a strict definition of lead failure, or the great skill of the implanting physicians. Interestingly, patients who underwent ICD lead revision for malfunction had an 8-fold higher incidence of experiencing another lead failure; this higher incidence underscores the important contribution of patient factors to ICD lead performance. Causes of malfunction were similar to those in prior published reports and most often were related to insulation defects and lead fractures. Inappropriate ICD therapies occurred in 76% of those patients who experienced a lead malfunction.Like the Eckstein study, a number of prior published reports inform us about the reliability and durability of ICD leads4–11 (Figure 1). Reported ICD lead “survival” varies from 91% to 99% at 2 years, 85% to 98% at 5 years, and 60% to 72% at 8 years. Several conclusions may be drawn from review of the data: The definition of ICD lead “survival” or lead “performance” varies from study to study. Most commonly in published studies, lead malfunction is defined as electrical abnormalities on lead testing, a chest roentgenogram consistent with a fracture, or evidence of oversensing unrelated to cardiac signals. Other studies rely on physician clinical judgment and require replacement of the ICD lead in order to consider the lead to have malfunctioned. In most published studies, thresholds for action are poorly defined and ambiguous. The varying definitions make it difficult to compare study to study and lead to lead.ICD lead performance varies by model. Although conceptually simple, ICD leads are complicated devices with lead designs that vary from model to model. These design differences may include variations in insulation, cable/conductor, length, diameter, and fixation mechanism. Pooling ICD lead models for analysis, therefore, is potentially problematic, because occasionally individual ICD leads underperform relative to the average. On the other hand, understanding the average durability and reliability of an ICD lead is useful as a standard to which other leads may be compared.Patient and physician characteristics affect ICD lead performance. Measuring lead performance is challenged by the impact of certain patient characteristics (such as size, activity, and anatomy) and physician characteristics (such as implantation skill, technique, and experience) on lead performance.Clinical presentation of ICD lead failure varies. ICD lead malfunction may occasionally be catastrophic and life threatening, such as when the lead fails to deliver a needed high-voltage therapy. More often, patients present with inappropriate shocks or abnormal electrical parameters detected on routine testing. Some algorithms have been developed to detect lead abnormalities before they progress to a clinical lead failure, but unfortunately these are effective only in a minority of patients.The tools available to detect impending ICD lead failure are limited. Fluoroscopy, x-ray, electrical testing, or direct visualization may be used to detect lead abnormalities, but in many respects these methods are too rudimentary and imprecise. Novel tools (eg, imaging and electrical) need to be developed to identify lead abnormalities sooner, both to prevent untoward clinical events and to better monitor lead performance earlier in the lifetime of the lead.Download figureDownload PowerPointFigure 1. The results of selected studies of ICD lead performance are shown. To be included, studies had to (1) be published in a peer-reviewed journal after 1999, (2) provide follow-up for at least 18 months after implantation, and (3) statistically account for patients who had died or were lost to follow-up. The data point represents the point estimate of the study for ICD lead survival. The size of the data point is proportional to the total number of patients in the study. The white data point represents the study by Eckstein et al,3 published in the current issue of Circulation. The great variation observed in ICD lead survival is due to a variety of factors including variable study definitions of ICD lead malfunction, variable performance of different ICD lead models, and the impact of patient characteristics and physician implantation techniques on ICD lead performance. Primary author, year of publication, and number of patients in each study are displayed in the legend.Given the aforementioned complexities of monitoring ICD lead performance and the weakness of the published studies, it is not surprising that reports of ICD lead performance have yielded varying results (Figure 1).Whereas ICD lead malfunction mechanisms are generally well defined and understood, the lack of standardized ICD lead performance definitions hinders data collection and analysis, as well as communication about device performance. In the wake of recent high-profile ICD lead performance questions, such as those affecting the Medtronic Sprint Fidelis and the St. Jude Medical Riata ICD leads, the Heart Rhythm Society announced in March 2008 the formation of the Task Force on Lead Performance Policies and Guidelines.12 The task force will make recommendations to the US Food and Drug Administration, Congress, industry, physicians, and patients on lead performance, communication of lead performance, surveillance, threshold for activation of lead advisories, communication after abnormal performance is identified, clinical management of lead performance issues, and regulatory considerations.A number of on-going efforts will greatly enhance our understanding of ICD lead performance in the coming months and years. The National Cardiovascular Data Registry ICD Registry will incorporate ICD leads.12 The US Food and Drug Administration is developing HeartNet, a sentinel network of electrophysiology laboratories throughout the United States, specially trained to report adverse events and device malfunctions, including those affecting ICD leads. Independent registries, such as the Multicenter Registry,13 continue to carefully monitor device performance and to provide early warning signals for devices whose performance expectations are not met. In addition, a number of ICD lead manufacturers have embarked on prospective ICD lead clinical studies and registries to better monitor ICD lead performance. Wireless remote monitoring of ICD lead function also offers enormous potential to identify performance issues early and to provide an automated warning system to improve patient safety (Figure 2). Download figureDownload PowerPointFigure 2. Information obtained remotely during routine follow-up from an ICD patient is shown. Right ventricular lead impedance, measured in ohms, is displayed. The lead impedance is stable in the 400 to 600 Ω range from January 2006 (*) until a sudden increase in lead impedance is noted (arrow). The high impedance is consistent with a lead fracture, and this patient’s ICD lead was replaced. The patient was asymptomatic, and the early detection afforded by the remote monitoring likely prevented an inappropriate shock or other adverse clinical event.ICDs are clinically proven to improve survival in select patients at risk for sudden cardiac death. Although ICD leads are a mature technology, monitoring of these devices remains critical to inform physicians and patients about device performance and to identify underperforming products as early as possible. Ongoing efforts to standardize definitions of performance, improve timeliness of data collection, and enhance performance reporting are underway and will benefit the millions of patients who enjoy the benefits of these devices.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Dr Maisel is a US Food and Drug Administration consultant, a member of the Medicare Coverage Advisory Committee, and Cochair of the Heart Rhythm Society Task Force on Lead Performance Policies and Guidelines. Dr Kramer is a member of the US Food and Drug Administration Medical Device Fellowship Program. The opinions expressed in this article are those of the authors and do not necessarily represent the practices, policies, positions, or opinions of the Food and Drug Administration, Center for Medicare and Medicaid Services, or the Heart Rhythm Society.DisclosuresNone.FootnotesCorrespondence to William H. Maisel, MD, MPH, Medical Device Safety Institute, Beth Israel Deaconess Medical Center, 185 Pilgrim Rd, Baker 4, Boston, MA 02215. E-mail [email protected] References 1 Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, Langer A, Heilman MS, Kolenik SA, Fischell RE, Weisfeldt ML. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980; 303: 322–324.CrossrefMedlineGoogle Scholar2 Maisel WH. Transvenous implantable cardioverter defibrillator leads: the weakest link. Circulation. 2007; 115: 2461–2463.LinkGoogle Scholar3 Eckstein J, Koller MT, Zabel M, Kalusche D, Schaer BA, Osswald S, Sticherling C. Necessity for surgical revision of defibrillator leads implanted long-term: causes and management. Circulation. 2008; 117: 21:2727–2733.MedlineGoogle Scholar4 Aass H, Ilvento J. Short and medium time experience with a tined, multilumen steroid eluting defibrillation lead. J Interv Card Electrophysiol. 2002; 6: 81–86.CrossrefMedlineGoogle Scholar5 Kron J, Herre J, Renfroe EG, Rizo-Patron C, Raitt M, Halperin B, Gold M, Goldner B, Wathen M, Wilkoff B, Olarte A, Yao Q. Lead- and device-related complications in the Antiarrhythmics Versus Implantable Defibrillators trial. Am Heart J. 2001; 141: 92–98.CrossrefMedlineGoogle Scholar6 Dorwarth U, Frey B, Gugas M, Matis T, Fiek M, Schmoeckel M, Remp P, Durchlaub I, Gerth A, Steinbeck G, Hoffmann E. Transvenous defibrillation leads: high incidence of failure during long-term follow-up. J Cardiovasc Electrophysiol. 2003; 14: 38–43.CrossrefMedlineGoogle Scholar7 Ellenbogen KA, Wood MA, Shepard RK, Clemo HF, Vaughn T, Holloman K, Dow M, Leffler J, Abeyratne A, Verness D. Detection and management of an implantable cardioverter defibrillator lead failure: incidence and clinical implications. J Am Coll Cardiol. 2003; 41: 73–80.CrossrefMedlineGoogle Scholar8 Luria D, Glikson M, Brady PA, Lexvold NY, Rasmussen MJ, Hodge DO, Chugh SS, Rea RF, Hayes DL, Hammill SC, Friedman PA. Predictors and mode of detection of transvenous lead malfunction in implantable defibrillators. Am J Cardiol. 2001; 87: 901–904.CrossrefMedlineGoogle Scholar9 Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, Saggau W, Weisse U, Seidl K. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007; 115: 2474–2480.LinkGoogle Scholar10 Kitamura S, Satomi K, Kurita T, Shimizu W, Suyama K, Aihara N, Niwaya K, Kobayashi J, Kamakura S. Long-term follow-up of transvenous defibrillation leads: high incidence of fracture in coaxial polyurethane lead. Circ J. 2006; 70: 273–277.CrossrefMedlineGoogle Scholar11 Hauser RG, Cannom D, Hayes DL, Parsonnet V, Hayes J, Ratliff N III, Tyers GF, Epstein AE, Vlay SC, Furman S, Gross J. Long-term structural failure of coaxial polyurethane implantable cardioverter defibrillator leads. Pacing Clin Electrophysiol. 2002; 25: 879–882.CrossrefMedlineGoogle Scholar12 Lindsay BD. Task Force on Lead Performance. Available at: http://www.hrsonline.org/News/taskforce_leadperformance.cfm?zbrandid=3077&zidType=CH&zid=813428&zsubscriberId=751606938. Accessed March 30, 2008.Google Scholar13 Multicenter Registry of Pacemaker, ICD Pulse Generator, and Lead Failures. Available at: http://www.pacerandicdregistry.com/mhif/. Accessed March 30, 2008.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByFong K, Ng C, Wang Y, Yeo C and Tan V (2022) Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Systematic Review and Meta‐Analysis of Randomized Trials and Propensity Score–Matched Studies, Journal of the American Heart Association, 11:11, Online publication date: 7-Jun-2022. Sarubbi B, Colonna D, Correra A, Romeo E, D’Alto M, Palladino M, Virno S, D’Onofrio A and Russo M (2021) Subcutaneous implantable cardioverter defibrillator in children and adolescents: results from the S-ICD “Monaldi care” registry, Journal of Interventional Cardiac Electrophysiology, 10.1007/s10840-021-00966-4, 63:2, (283-293), Online publication date: 1-Mar-2022. Massaro G, Diemberger I, Ziacchi M, Angeletti A, Statuto G, Galiè N and Biffi M (2021) A Historical Perspective of Cardiac Implantable Electronic Device Infection: How a Menace Can Drive Technological and Clinical Improvement, Hearts, 10.3390/hearts2020016, 2:2, (202-212) Shinohara T, Abe I, Hirota K, Kondo H, Fukui A, Akioka H, Teshima Y, Yufu K, Nakagawa M and Takahashi N (2020) Usefulness of subcutaneous implantable cardioverter-defibrillator therapy in patients with Brugada syndrome, Heart and Vessels, 10.1007/s00380-020-01683-0, 36:2, (260-266), Online publication date: 1-Feb-2021. Richardson C, Prempeh J, Gordon K, Poyser T and Tiesenga F Surgical Techniques, Complications, and Long-Term Health Effects of Cardiac Implantable Electronic Devices, Cureus, 10.7759/cureus.13001 Cobb V, Ezzat V, Higgins F, Lambiase P, Lowe M, Segal O and Chow A (2020) Chronic performance of Riata 1580 and Endotak 0158 ICD leads: A single center 10‐year experience, Pacing and Clinical Electrophysiology, 10.1111/pace.13917, 43:7, (698-704), Online publication date: 1-Jul-2020. Magnusson P and Wimo A (2020) Health economic evaluation of implantable cardioverter defibrillators in hypertrophic cardiomyopathy in adults, International Journal of Cardiology, 10.1016/j.ijcard.2020.02.055, 311, (46-51), Online publication date: 1-Jul-2020. Probst V, Boveda S, Sadoul N, Marquié C, Chauvin M, Mondoly P, Gras D, Jacon P, Defaye P, Leclercq C and Anselme F (2020) Subcutaneous implantable cardioverter defibrillator indication in prevention of sudden cardiac death in difficult clinical situations: A French expert position paper, Archives of Cardiovascular Diseases, 10.1016/j.acvd.2020.03.011, 113:5, (359-366), Online publication date: 1-May-2020. Mattsson G and Magnusson P (2020) Long‐term follow‐up of implantable cardioverter defibrillator patients with regard to appropriate therapy, complications, and mortality, Pacing and Clinical Electrophysiology, 10.1111/pace.13869, 43:2, (245-253), Online publication date: 1-Feb-2020. Deharo J and Martignani C (2020) Prevention of Device Infection: New Implantable Devices Infections of Cardiac Implantable Devices, 10.1007/978-3-030-46255-0_10, (153-175), . Essandoh M, Holecko J, Warsame I and Papadimos T (2019) Predictors of Intensive Care Unit Admission After Transvenous Lead Extraction: A Plea for a Risk Scoring System, Journal of Cardiothoracic and Vascular Anesthesia, 10.1053/j.jvca.2019.02.047, 33:7, (1852-1854), Online publication date: 1-Jul-2019. Monaco F, Di Tomasso N, Landoni G, Nardelli P, Radinovic A, Melillo F, D'Angelo G, Della Bella P, Zangrillo A and Mazzone P (2019) Predictors of Intensive Care Unit Admission in Patients Undergoing Lead Extraction: A 10-Year Observational Study in a High-Volume Center, Journal of Cardiothoracic and Vascular Anesthesia, 10.1053/j.jvca.2019.02.012, 33:7, (1845-1851), Online publication date: 1-Jul-2019. Magnusson P, V. Pergolizzi J and Ann LeQuang J (2019) The Subcutaneous Implantable Cardioverter-Defibrillator Cardiac Pacing and Monitoring - New Methods, Modern Devices, 10.5772/intechopen.80859 Niehues P, Frommeyer G, Reinke F and Eckardt L (2018) Subkutan implantierbarer Kardioverter-DefibrillatorSubcutaneous implantable cardioverter–defibrillator, Herzschrittmachertherapie + Elektrophysiologie, 10.1007/s00399-018-0593-8, 29:4, (349-354), Online publication date: 1-Dec-2018. Sperzel J, Hamm C and Hain A (2018) Leadless pacingSondenlose Herzschrittmacher, Herz, 10.1007/s00059-018-4752-9, 43:7, (605-611), Online publication date: 1-Nov-2018. Segreti L, Giannotti Santoro M, Di Cori A, Zucchelli G, Viani S, De Lucia R, Della Tommasina V, Barletta V, Paperini L, Soldati E and Bongiorni M (2018) Utility of risk scores to predict adverse events in cardiac lead extraction, Expert Review of Cardiovascular Therapy, 10.1080/14779072.2018.1513325, 16:10, (695-705), Online publication date: 3-Oct-2018. Alkar B, Mattsson G and Magnusson P (2018) Ischemic Cardiomyopathy: Contemporary Clinical Management Current Perspectives on Cardiomyopathies, 10.5772/intechopen.76723 Boveda S, Lenarczyk R, Fumagalli S, Tilz R, Gościńska-Bis K, Kempa M, Defaye P, Marquié C, Capucci A, Ueberham L and Dagres N (2018) Factors influencing the use of subcutaneous or transvenous implantable cardioverter-defibrillators: results of the European Heart Rhythm Association prospective survey, EP Europace, 10.1093/europace/euy009, 20:5, (887-892), Online publication date: 1-May-2018. Mithani A, Kath H, Hunter K, Andriulli J, Ortman M, Field J and Russo A (2017) Characteristics and early clinical outcomes of patients undergoing totally subcutaneous vs. transvenous single chamber implantable cardioverter defibrillator placement, EP Europace, 10.1093/europace/eux026, 20:2, (308-314), Online publication date: 1-Feb-2018. Hussein A and Chung M (2018) Prevention of Sudden Cardiac Death Chronic Coronary Artery Disease, 10.1016/B978-0-323-42880-4.00022-4, (321-336), . Winter J, Siekiera M, Shin D, Meyer C, Kröpil P, Clahsen H and O'Connor S (2016) Intermuscular technique for implantation of the subcutaneous implantable cardioverter defibrillator: long-term performance and complications, EP Europace, 10.1093/europace/euw297, 19:12, (2036-2041), Online publication date: 1-Dec-2017. Looi K, Lever N, Tang A and Agarwal S (2017) Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?, Heart Failure Reviews, 10.1007/s10741-017-9602-y, 22:3, (305-316), Online publication date: 1-May-2017. (2017) Current status and issues of Implantable Cardioverter Defibrillator, Iryou kikigaku (The Japanese journal of medical instrumentation), 10.4286/jjmi.87.32, 87:1, (32-39), . Sideris S, Archontakis S, Gatzoulis K, Anastasakis A, Sotiropoulos I, Arsenos P, Kasiakogias A, Terentes D, Trachanas K, Paschalidis E, Tousoulis D and Kallikazaros I (2017) The subcutaneous ICD as an alternative to the conventional ICD system: Initial experience in Greece and a review of the literature, Hellenic Journal of Cardiology, 10.1016/j.hjc.2017.01.010, 58:1, (4-16), Online publication date: 1-Jan-2017. Cuoco F and Gold M (2017) Subcutaneous and Epicardial Defibrillators Clinical Cardiac Pacing, Defibrillation and Resynchronization Therapy, 10.1016/B978-0-323-37804-8.00017-1, (482-489), . Bongiorni M, Di Cori A, Segreti L, Zucchelli G, Viani S, Paperini L, Menichetti F, Coluccia G and Soldati E (2016) Where is the future of cardiac lead extraction heading?, Expert Review of Cardiovascular Therapy, 10.1080/14779072.2016.1220832, 14:10, (1197-1203), Online publication date: 2-Oct-2016. Boveda S, Lenarczyk R, Haugaa K, Fumagalli S, Madrid A, Defaye P, Broadhurst P and Dagres N (2016) Implantation of subcutaneous implantable cardioverter defibrillators in Europe: results of the European Heart Rhythm Association survey, Europace, 10.1093/europace/euw258, 18:9, (1434-1439), Online publication date: 1-Sep-2016. GOOD E, CAKULEV I, ORLOV M, HIRSH D, SIMELES J, MOHR K, MOLL P and BLOOM H (2016) Long-Term Evaluation of Biotronik Linox and Linox smart Implantable Cardioverter Defibrillator Leads , Journal of Cardiovascular Electrophysiology, 10.1111/jce.12971, 27:6, (735-742), Online publication date: 1-Jun-2016. Providência R, Kramer D, Pimenta D, Babu G, Hatfield L, Ioannou A, Novak J, Hauser R and Lambiase P (2015) Transvenous Implantable Cardioverter‐Defibrillator (ICD) Lead Performance: A Meta‐Analysis of Observational Studies, Journal of the American Heart Association, 4:11, Online publication date: 29-Oct-2015.Kramer D, Hatfield L, McGriff D, Ellis C, Gura M, Samuel M, Retel L and Hauser R (2015) Transvenous Implantable Cardioverter‐Defibrillator Lead Reliability: Implications for Postmarket Surveillance, Journal of the American Heart Association, 4:6, Online publication date: 15-Jun-2015. Zipse M, Schuller J, Steckman D, Katz D, Tzou W, Nguyen D, Aleong R, Sung R, Tompkins C, Varosy P and Sauer W (2015) Measured Lead Parameters and Electrogram Sensing Over Time in Patients With Cardiac Sarcoidosis and an Implanted Cardiac-Defibrillator, JACC: Clinical Electrophysiology, 10.1016/j.jacep.2015.02.013, 1:1-2, (94-102), Online publication date: 1-Mar-2015. Cipolletta L and Ricciotti J (2015) The Role of Home Monitoring Clinical Cases in Cardiology, 10.1007/978-3-319-19926-9_28, (325-336), . Sanghera R, Sanders R, Husby M and Bentsen J (2014) Development of the subcutaneous implantable cardioverter-defibrillator for reducing sudden cardiac death, Annals of the New York Academy of Sciences, 10.1111/nyas.12550, 1329:1, (1-17), Online publication date: 1-Nov-2014. Crozier I, Hooks D, Daly M and Melton I (2014) How the Subcutaneous Implantable Cardioverter Defibrillator Works, Cardiac Electrophysiology Clinics, 10.1016/j.ccep.2014.02.005, 6:2, (285-295), Online publication date: 1-Jun-2014. Majithia A, Estes N and Weinstock J (2014) Advances in Sudden Death Prevention: The Emerging Role of a Fully Subcutaneous Defibrillator, The American Journal of Medicine, 10.1016/j.amjmed.2013.10.018, 127:3, (188-194), Online publication date: 1-Mar-2014. Gold M and Swerdlow C (2014) The Implantable Cardioverter-Defibrillator Cardiac Pacing and ICDs, 10.1002/9781118459553.ch8, (323-373) Grace A (2014) The subcutaneous implantable cardioverter-defibrillator, Current Opinion in Cardiology, 10.1097/HCO.0000000000000031, 29:1, (10-19), Online publication date: 1-Jan-2014. Forleo G, Di Biase L, Mantica M, Panattoni G, Santamaria M, Parisi Q, Sergi D, Papavasileiou L, Santini L, Tondo C, Natale A and Romeo F (2013) First clinical experience with the new four-pole standard connector for high-voltage ICD leads. Early results of a multicenter comparison with conventional implant outcomes, Journal of Interventional Cardiac Electrophysiology, 10.1007/s10840-013-9814-6, 38:1, (11-18), Online publication date: 1-Oct-2013. Gard J, Cha Y and Friedman P (2013) Leadless Pacing and Defibrillation Systems, Cardiac Electrophysiology Clinics, 10.1016/j.ccep.2013.05.009, 5:3, (327-335), Online publication date: 1-Sep-2013. Seifert M, Neuss M, Schöpp M, Koban C and Butter C (2013) Laufzeit und Komplikationen (außer Infektionen) von ICD-SondenLead survival and complications (except infections), Herzschrittmachertherapie + Elektrophysiologie, 10.1007/s00399-013-0278-2, 24:3, (141-147), Online publication date: 1-Sep-2013. Reinke F, Löher A, Köbe J and Eckardt L (2013) Gegenwärtiger Stand und Probleme vollständig subkutaner ICD-Systeme (S-ICD®)Current status and problems of the entirely subcutaneous ICD (S-ICD®), Herzschrittmachertherapie + Elektrophysiologie, 10.1007/s00399-013-0277-3, 24:3, (165-170), Online publication date: 1-Sep-2013. Olde Nordkamp L, Dabiri Abkenari L, Boersma L, Maass A, de Groot J, van Oostrom A, Theuns D, Jordaens L, Wilde A and Knops R (2012) The Entirely Subcutaneous Implantable Cardioverter-Defibrillator, Journal of the American College of Cardiology, 10.1016/j.jacc.2012.06.053, 60:19, (1933-1939), Online publication date: 1-Nov-2012. Rowley C, Lobodzinski S and Gold M (2012) The Subcutaneous Defibrillator, Current Treatment Options in Cardiovascular Medicine, 10.1007/s11936-012-0196-3, 14:5, (550-557), Online publication date: 1-Oct-2012. Cappato R, Smith W, Hood M, Crozier I, Jordaens L, Spitzer S, Ardashev A, Boersma L, Lupo P, Grace A and Bardy G (2012) Subcutaneous chronic implantable defibrillation systems in humans, Journal of Interventional Cardiac Electrophysiology, 10.1007/s10840-012-9665-6, 34:3, (325-332), Online publication date: 1-Sep-2012. Rowley C and Gold M (2012) Subcutaneous Implantable Cardioverter Defibrillator, Circulation: Arrhythmia and Electrophysiology, 5:3, (587-593), Online publication date: 1-Jun-2012. Crozier I and Smith W (2012) Modern Device Technologies, Heart, Lung and Circulation, 10.1016/j.hlc.2011.11.001, 21:6-7, (320-327), Online publication date: 1-Jun-2012. Lupo P, Pelissero G, Ali H, Sanghera R and Cappato R (2012) Development of an Entirely Subcutaneous Implantable Cardioverter-Defibrillator, Progress in Cardiovascular Diseases, 10.1016/j.pcad.2012.03.006, 54:6, (493-497), Online publication date: 1-May-2012. Olde Nordkamp L, Knops R, Bardy G, Blaauw Y, Boersma L, Bos J, Delnoy P, van Dessel P, Driessen A, de Groot J, Herrman J, Jordaens L, Kooiman K, Maass A, Meine M, Mizusawa Y, Molhoek S, van Opstal J, Tijssen J and Wilde A (2012) Rationale and design of the PRAETORIAN trial: A Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy, American Heart Journal, 10.1016/j.ahj.2012.02.012, 163:5, (753-760.e2), Online publication date: 1-May-2012. DEYELL M and CALLANS D (2011) Between an ICD and a Hard Place, Journal of Cardiovascular Electrophysiology, 10.1111/j.1540-8167.2011.02092.x, 22:10, (1120-1122), Online publication date: 1-Oct-2011. Smith T, van Dessel P, Theuns D, Muskens-Heemskerk A, van Domburg R, Wilde A and Jordaens L (2011) Health care utilisation after defibrillator implantation for primary prevention according to the guidelines in 2 Dutch academic medical centres, Netherlands Heart Journal, 10.1007/s12471-011-0176-3, 19:10, (405-411), Online publication date: 1-Oct-2011. Crozier I (2011) The subcutaneous defibrillator will replace the transvenous defibrillator, Journal of Interventional Cardiac Electrophysiology, 10.1007/s10840-011-9570-4, 32:1, (73-77), Online publication date: 1-Oct-2011. Köbe J, Zumhagen S, Reinke F, Schulze-Bahr E and Eckardt L (2011) Komplett subkutaner Kardioverter-Defibrillator (S-ICD®)Totally subcutaneous cardioverter-defibrillator (S-ICD®), Herz, 10.1007/s00059-011-3508-6, 36:7, (586-591), Online publication date: 1-Oct-2011. Gupta A, Al-Ahmad A and Wang P (2011) Subcutaneous Implantable Cardioverter-Defibrillator Technology, Heart Failure Clinics, 10.1016/j.hfc.2011.01.005, 7:2, (287-294), Online publication date: 1-Apr-2011. Diemberger I, Biffi M, Martignani C and Boriani G (2014) From lead management to implanted patient management: indications to lead extraction in pacemaker and cardioverter–defibrillator systems, Expert Review of Medical Devices, 10.1586/erd.10.80, 8:2, (235-255), Online publication date: 1-Mar-2011. Miyamoto S, Nakano Y, Okahara S, Takahashi H, Matsuzaki H, Oda N, Imai K, Sueda T and Kihara Y (2011) Examination of the Effective Utilization of the CARELINK® Remote Monitoring System after its Introduction, Journal of Arrhythmia, 10.4020/jhrs.27.126, 27:2, (126-130), . Miyamoto S, Nakano Y, Okahara S, Takahashi H, Matsuzaki H, Oda N, Imai K, Sueda T and Kihara Y (2011) Examination of the Effective Utilization of the CARELINK® Remote Monitoring System after its Introduction, Journal of Arrhythmia, 10.1016/S1880-4276(11)80020-7, 27:2, (126-130), . Kramer D and Maisel W (2011) Guidelines for Managing Pacemaker and Implantable Defibrillator Advisories Clinical Cardiac Pacing, Defibrillation and Resynchronization Therapy, 10.1016/B978-1-4377-1616-0.00034-5, (1028-1039), . Smith W, Bardy G, Hood M and Grace A (2011) Subcutaneous Implantable Cardioverter-Defibrillators Clinical Cardiac Pacing, Defibrillation and Resynchronization Therapy, 10.1016/B978-1-4377-1616-0.00019-9, (428-433), . BEN MORRISON T, REA R, HODGE D, CRUSAN D, KOESTLER C, ASIRVATHAM S, BRADLEY D, SHEN W, MUNGER T, HAMMILL S and FRIEDMAN P (2010) Risk Factors for Implantable Defibrillator Lead Fracture in a Recalled and a Nonrecalled Lead, Journal of Cardiovascular Electrophysiology, 10.1111/j.1540-8167.2009.01683.x, 21:6, (671-677) Scott P, Chungh A, Zeb M, Yue A, Roberts P and Morgan J (2009) Is the use of an additional pace/sense lead the optimal strategy for the avoidance of lead extraction in defibrillation lead failure? A single-centre experience, Europace, 10.1093/europace/eup406, 12:4, (522-526), Online publication date: 1-Apr-2010. Lampert R and Goldberger Z (2010) Implantable Cardioverter-Defibrillators Device Therapy in Heart Failure, 10.1007/978-1-59745-424-7_6, (155-184), . Kusumoto F and Goldschlager N (2010) Remote Monitoring of Patients With Implanted Cardiac Devices, Clinical Cardiology, 10.1002/clc.20688, 33:1, (10-17), Online publication date: 1-Jan-2010. Gupta A, Al-Ahmad A and Wang P (2009) Subcutaneous Implantable Cardioverter-Defibrillator Technology, Cardiac Electrophysiology Clinics, 10.1016/j.ccep.2009.08.012, 1:1, (147-154), Online publication date: 1-Dec-2009. Maisel W, Hauser R, Hammill S, Hauser R, Ellenbogen K, Epstein A, Hayes D, Alpert J, Berger R, Curtis A, Dubin A, Estes N, Gura M, Krahn A, Lampert R, Lindsay B and Wilkoff B (2009) Recommendations from the Heart Rhythm Society Task Force on Lead Performance Policies and Guidelines, Heart Rhythm, 10.1016/j.hrthm.2009.04.024, 6:6, (869-885), Online publication date: 1-Jun-2009. Duray G, Schmitt J, Cicek-Hartvig S, Hohnloser S and Israel C (2008) Complications leading to surgical revision in implantable cardioverter defibrillator patients: comparison of patients with single-chamber, dual-chamber, and biventricular devices, EP Europace, 10.1093/europace/eun322, 11:3, (297-302), Online publication date: 1-Mar-2009., Online publication date: 1-Mar-2009. Maisel W (2008) Implantable cardioverter-defibrillator lead complication: When is an outbreak out of bounds?, Heart Rhythm, 10.1016/j.hrthm.2008.10.014, 5:12, (1673-1674), Online publication date: 1-Dec-2008. Goette A, Cantu F, van Erven L, Geelen P, Halimi F, Merino J and Morgan J (2008) Performance and survival of transvenous defibrillation leads: need for a European data registry, Europace, 10.1093/europace/eun301, 11:1, (31-34) Sherrid M and Daubert J (2008) Risks and Challenges of Implantable Cardioverter-Defibrillators in Young Adults, Progress in Cardiovascular Diseases, 10.1016/j.pcad.2008.10.001, 51:3, (237-263), Online publication date: 1-Nov-2008. May 27, 2008Vol 117, Issue 21 Advertisement Article InformationMetrics https://doi.org/10.1161/CIRCULATIONAHA.108.776807PMID: 18506015 Originally publishedMay 27, 2008 KeywordsregistriesdefibrillationEditorialsdeath, suddentachyarrhythmiasPDF download Advertisement SubjectsCatheter Ablation and Implantable Cardioverter-Defibrillator